Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Carls, E. Tuttle, R. Tan, Johnny Huynh, J. Yee, S. Edelman, W. Polonsky (2017)
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 DiabetesDiabetes Care, 40
K. Khunti, M. Wolden, B. Thorsted, M. Andersen, M. Davies (2013)
Clinical Inertia in People With Type 2 DiabetesDiabetes Care, 36
HJ Smolen, DR Murphy, JC Gahn, X Yu, BH Curtis (2014)
The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitusJ Manag Care Spec Pharm., 20
Gérard Reach (2008)
Patient non-adherence and healthcare-provider inertia are clinical myopia.Diabetes & metabolism, 34 4 Pt 1
J. Wofford (2002)
Clinical inertia.Annals of internal medicine, 137 6
R. Ayyagari, Wenhui Wei, David Cheng, C. Pan, J. Signorovitch, E. Wu (2015)
Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 2
Gérard Reach, V. Pechtner, R. Gentilella, Antonella Corcos, A. Ceriello (2017)
Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus.Diabetes & metabolism, 43 6
(2017)
Standards of medical care in diabetes—2017Diabetes Care, 40
Sarah Casagrande, J. Fradkin, S. Saydah, Keith Rust, C. Cowie (2013)
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010Diabetes Care, 36
P Levin, J Lin, W Wei (2014)
Initiating injectable therapy in US managed care patients with diabetesAm J Pharm Benefits., 6
Alan Garber, Martin Abrahamson, Joshua Barzilay, Lawrence Blonde, Zachary Bloomgarden, Michael Bush, Samuel Dagogo-Jack, Ralph DeFronzo, Daniel Einhorn, Vivian Fonseca, J. Garber, W. Garvey, George Grunberger, Y. Handelsman, Irl Hirsch, P. Jellinger, Janet McGill, Jeffrey Mechanick, P. Rosenblit, Guillermo Umpierrez (2017)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 23 2
K. Khunti, M. Wolden, B. Thorsted, M. Andersen, M. Davies (2013)
A retrospective cohort study of more than 80,000 people
H. Smolen, D. Murphy, J. Gahn, Xueting Yu, B. Curtis (2014)
The Evaluation of Clinical and Cost Outcomes Associated with Earlier Initiation of Insulin in Patients with Type 2 Diabetes MellitusJournal of Managed Care Pharmacy : JMCP, 20
R. Grant, E. Cagliero, A. Dubey, C. Gildesgame, H. Chueh, Michael Barry, Daniel Singer, D. Nathan, J. Meigs (2004)
Clinical inertia in the management of Type 2 diabetes metabolic risk factorsDiabetic Medicine, 21
Research Triangle Institute. Ethics and Human Research Protection Web site. www.rti.org/ethicsand-human-research-protection
V. Fonseca, N. Clark (2006)
Standards of Medical Care in Diabetes: Response to PowerDiabetes Care, 29
G. Nichols, Y. Koo, Sonali Shah (2007)
Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic ControlJournal of General Internal Medicine, 22
P. Levin, Steve Zhou, J. Gill, Wenhui Wei (2015)
Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 DiabetesJournal of Managed Care & Specialty Pharmacy, 21
G. Riley (2009)
Administrative and Claims Records as Sources of Health Care Cost DataMedical Care, 47
(Research Triangle Institute. Ethics and Human Research Protection Web site. www.rti.org/ethics-and-human-research-protection. Accessed 19 Oct 2017.)
Research Triangle Institute. Ethics and Human Research Protection Web site. www.rti.org/ethics-and-human-research-protection. Accessed 19 Oct 2017.Research Triangle Institute. Ethics and Human Research Protection Web site. www.rti.org/ethics-and-human-research-protection. Accessed 19 Oct 2017., Research Triangle Institute. Ethics and Human Research Protection Web site. www.rti.org/ethics-and-human-research-protection. Accessed 19 Oct 2017.
M. Dalal, L. Xie, O. Baser, A. Digenio (2015)
Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 21 1
P. Levin, Wenhui Wei, A. Vlajnic, C. Pan, Lin Xie, Jay Lin, and Baser (2014)
Initiating Injectable Therapy in US Managed Care Patients With DiabetesThe American Journal of Managed Care, 6
A. Garber (2018)
IN RESPONSE TO AUTHORS' RESPONSE TO KARL Z. NADOLSKY, DO, RE: CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 24 5
S. Davis, Wenhui Wei, S. Garg (2011)
Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 17 6
A. Garber, M. Abrahamson, J. Barzilay, L. Blonde, Z. Bloomgarden, Michael Bush, S. Dagogo-Jack, R. DeFronzo, D. Einhorn, V. Fonseca, J. Garber, W. Garvey, G. Grunberger, Y. Handelsman, I. Hirsch, P. Jellinger, J. McGill, J. Mechanick, P. Rosenblit, G. Umpierrez (2018)
AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
Jonathan Brown, G. Nichols (2003)
Slow response to loss of glycemic control in type 2 diabetes mellitus.The American journal of managed care, 9 3
(Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017 (Epub ahead of print).)
Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017 (Epub ahead of print).Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017 (Epub ahead of print)., Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017 (Epub ahead of print).
M. Bonafede, A. Chandran, S. Dimario, R. Saltiel-Berzin, Drilon Saliu (2016)
Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database studyBMJ Open Diabetes Research & Care, 4
M. Peyrot, R. Rubin, K. Khunti (2010)
Addressing barriers to initiation of insulin in patients with type 2 diabetes.Primary care diabetes, 4 Suppl 1
E. Wagner, Nirmala Sandhu, K. Newton, D. Mcculloch, Scott Ramsey, L. Grothaus (2001)
Effect of improved glycemic control on health care costs and utilization.JAMA, 285 2
K Khunti, ML Wolden, BL Thorsted, M Andersen, MJ Davies (2013)
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 peopleDiabetes Care, 36
Alex Fu, John Sheehan (2016)
Treatment intensification for patients with type 2 diabetes and poor glycaemic controlDiabetes, 18
(Health and Human Services. Code of Federal Regulations. Title 45—Public Welfare Department of Health and Human Services. Part 46—Protection of Human Subjects. www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed 19 Oct 2017.)
Health and Human Services. Code of Federal Regulations. Title 45—Public Welfare Department of Health and Human Services. Part 46—Protection of Human Subjects. www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed 19 Oct 2017.Health and Human Services. Code of Federal Regulations. Title 45—Public Welfare Department of Health and Human Services. Part 46—Protection of Human Subjects. www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed 19 Oct 2017., Health and Human Services. Code of Federal Regulations. Title 45—Public Welfare Department of Health and Human Services. Part 46—Protection of Human Subjects. www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html. Accessed 19 Oct 2017.
S. Thayer, Wenhui Wei, E. Buysman, L. Brekke, W. Crown, M. Grabner, S. Raparla, R. Quimbo, M. Cziraky, Wenli Hu, R. Cuddihy (2013)
The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable TherapyAdvances in Therapy, 30
R. Roussel, P. Gourdy, J. Gautier, B. Guerci, D. Raccah, M. Behar, B. RobertJDetournay (2016)
Low rate of intensification in type 2 diabetic patients inadequately controlled with basal insulin: the INTERDIA studyDiabetes management, 6
M. Magee (2016)
DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED CARE SETTING.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22 2
Sec. (2000)
PART 50—PROTECTION OF HUMAN SUBJECTS
R. Roussel, B. Charbonnel, M. Behar, J. Gourmelen, C. Emery, B. Detournay (2016)
Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims StudyDiabetes Therapy, 7
M. Ajmera, A. Raval, Steve Zhou, Wenhui Wei, R. Bhattacharya, C. Pan, U. Sambamoorthi (2015)
A Real-World Observational Study of Time to Treatment Intensification Among Elderly Patients with Inadequately Controlled Type 2 Diabetes Mellitus.Journal of managed care & specialty pharmacy, 21 12
N. Bieszk, Shannon Reynolds, Wenhui Wei, C. Davis, P. Kamble, C. Uribe (2016)
"Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.Journal of managed care & specialty pharmacy, 22 9
D. Mauricio, L. Meneghini, J. Seufert, L. Liao, Hongwei Wang, Liyue Tong, A. Calí, P. Stella, P. Carita, K. Khunti (2017)
Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USADiabetes, Obesity & Metabolism, 19
GA Nichols, YH Koo, SN Shah (2007)
Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapyJ Gen Intern Med, 22
IntroductionTreatment guidelines recommend a stepwise approach to glycemia management in patients with type 2 diabetes (T2D), but this may result in uncontrolled glycated hemoglobin A1c (HbA1c) between steps. This retrospective analysis compared clinical and economic outcomes among patients with uncontrolled T2D initiating two oral antidiabetes drugs (OADs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or basal insulin in a real-world setting.MethodsAdults with T2D on OAD monotherapy were identified in the MarketScan claims database (2007–2014). Those initiating two OADs (simultaneously or sequentially), GLP-1 RAs, or basal insulin were selected (date of initiation was termed the ‘index date’); patients were required to have HbA1c > 7.0% in the 6 months pre-index date. HbA1c was compared from 6 months pre- to 1-year post-index. Annual all-cause healthcare utilization and costs were reported over the 1-year follow-up period.ResultsData for 6054 patients were analyzed (2-OAD, n = 4442; GLP-1 RA, n = 361; basal insulin, n = 1251). Baseline HbA1c was high in all cohorts, but highest in the basal-insulin cohort. Treatment initiation resulted in reductions in HbA1c in all cohorts, which was generally maintained throughout the follow-up period. Average HbA1c reductions from the 6 months pre- to 1 year post-index date were −1.2% for GLP-1 RA, −1.6% for OADs, and −1.8% for basal insulin. HbA1c < 7.0% at 1 year occurred in 32.6%, 47.5%, and 41.1% of patients, respectively. Annual healthcare costs (mean [SD]) were lowest for OAD (US$10,074 [$22,276]) followed by GLP-1 RA (US$14,052 [$23,829]) and basal insulin (US$18,813 [$37,332]).ConclusionDespite robust HbA1c lowering following treatment initiation, many patients did not achieve HbA1c < 7.0%. Basal insulin, generally prescribed for patients with high baseline HbA1c, was associated with a large reduction in HbA1c and with higher costs. Therapy intensification at an appropriate time could lead to clinical and economic benefits and should be investigated further.FundingSanofi U.S., Inc.
Diabetes Therapy – Springer Journals
Published: Jun 1, 2018
Keywords: Basal insulin; Clinical inertia; GLP-1 RA; Oral antidiabetes drugs; Treatment intensification; Type 2 diabetes
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.